65,437 trials
Secondary Hyperparathyroidism · Hemodialysis
Primary: The Percentage of Participants With a >=50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline Compared to the Average iPTH Obtained in the Last 3 Weeks…
Gastrointestinal Hemorrhage
Primary: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo — 22; 40 Participants
Non-erosive Gastroesophageal Reflux Disease
Primary: Percentage of Participants With Complete Relief of Heartburn at Final Evaluation — 20.9; 34.4; 43.6 Percentage of participants
Post-Menopausal Osteoporosis
Primary: Absolute Change From Baseline in Actual Glomerular Filtration Rate (GFR) (Using Abbreviated Modification of Diet in Renal Disease [MDRD] Formula) — 72.5; 71.5; 70.5…
Type 2 Diabetes Mellitus
Primary: Change in HbA1c (Percent) — -0.38; -0.68 Percent HbA1c — p=.012
HIV Infections
Primary: Percentage of Participants With Viral Load < 400 Copies /mL at Week 12. — 84; 86 Percentage of Participants
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8) — -7.97; -12.51; -15.28; -14.14 mmHg
Spasticity · Multiple Sclerosis
Primary: Number of Subjects Who Experience Treatment Failure. — 8; 17 Participants — p=0.013
Genital Herpes
Primary: Investigator-assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 4.25; 4.08 days
Osteoarthritis · Rheumatoid Arthritis · Chronic Low Back Pain
Primary: Number of Participants With Treatment Emergent Adverse Events — 55; 16 participants — p=0.4228
HIV Infections
Primary: Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the…
Metabolic Syndrome X
Primary: Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6 — -44.40; -36.50 percent change
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response (SVR) — 39; 58; 58; 69 Participants — p=0.0126
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants